Real-world experience with CPX-351 in high-risk acute myeloid leukemia

被引：6
|
作者：
Lemoli, Roberto M. [1 ,2 ,5 ,6 ]
Montesinos, Pau [3 ]
Jain, Akriti [4 ]
机构：
[1] IRCCS Osped Policlin San Martino, Genoa, Italy
[2] Univ Genoa, Clin Hematol, Genoa, Italy
[3] Hosp Univ & Politecn La Fe, Valencia, Spain
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] IRCCS Osped Policlin San Martino, Clin Hematol, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy
[6] Univ Genoa, Dept Internal Med & Med Specialties, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 185卷
关键词：
AML; Chemotherapy; CPX-351; Cytarabine; Daunorubicin; Real; -world; Measurable residual disease; RESIDUAL DISEASE; AML PATIENTS; SECONDARY; CHEMOTHERAPY; DAUNORUBICIN; AZACITIDINE; VENETOCLAX; CYTARABINE; ADULTS; AGE;
D O I：
10.1016/j.critrevonc.2023.103984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged & GE;1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses realworld studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.
引用
收藏
页数：10
相关论文
共 50 条
  • [31] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
  • [32] CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
    Garciaz, Sylvain
    Belhabri, Amine
    Guieze, Romain
    Goursaud, Laure
    Peterlin, Pierre
    Ledoux, Marie-Pierre
    Mathilde, Hunault-Berger
    Chebrek, Safia
    Robin, Jean-Baptiste
    Pigneux, Arnaud
    Bonnet, Sarah
    Bonmati, Caroline
    Bertoli, Sarah
    Braun, Thorsten
    Chantepie, Sylvain
    Meunier, Mathieu
    Heiblig, Mael
    Cluzeau, Thomas
    Jourdan, Eric
    Villate, Alban
    Recher, Christian
    Vey, Norbert
    Rey, Jerome
    BLOOD, 2023, 142
  • [33] Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
    Cluzeau, Thomas
    Guolo, Fabio
    Chiche, Edmond
    Minetto, Paola
    Rahme, Ramy
    Bertoli, Sarah
    Fianchi, Luana
    Micol, Jean-Baptiste
    Gottardi, Michele
    Peterlin, Pierre
    Galimberti, Sara
    Thomas, Xavier
    Rizzuto, Giuliana
    Legrand, Olivier
    Rondoni, Michela
    Raffoux, Emmanuel
    Bertani, Giambattista
    Caulier, Alexis
    D'Argenio, Michelina
    Bonmati, Caroline
    Billio, Atto
    Lejeune, Caroline
    Scappini, Barbara
    Pigneux, Arnaud
    Zappasodi, Patrizia
    Recher, Christan
    Grimaldi, Francesco
    Ades, Lionel
    Lemoli, Roberto M.
    BLOOD ADVANCES, 2025, 9 (04) : 752 - 758
  • [34] Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
    Chiche, Edmond
    Rahme, Ramy
    Bertoli, Sarah
    Dumas, Pierre-Yves
    Micol, Jean-Baptiste
    Hicheri, Yosr
    Pasquier, Florence
    Peterlin, Pierre
    Chevallier, Patrice
    Thomas, Xavier
    Loschi, Michael
    Genthon, Alexis
    Legrand, Ollivier
    Mohty, Mohamad
    Raffoux, Emmanuel
    Auberger, Patrick
    Caulier, Alexis
    Joris, Magalie
    Bonmati, Caroline
    Roth-Guepin, Gabrielle
    Lejeune, Caroline
    Pigneux, Arnaud
    Vey, Norbert
    Recher, Christian
    Ades, Lionel
    Cluzeau, Thomas
    BLOOD ADVANCES, 2021, 5 (01) : 176 - 184
  • [35] Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
    Talati, Chetasi
    Goldberg, Aaron D.
    Desai, Pinkal
    Chan, Onyee
    Famulare, Christopher
    Komrokji, Rami S.
    Kuykendall, Andrew T.
    Fernandez, Hugo F.
    Deutsch, Yehuda E.
    Padron, Eric
    List, Alan F.
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Tallman, Martin S.
    Sallman, David A.
    Sweet, Kendra L.
    BLOOD, 2018, 132
  • [36] Is it possible to extend the indications for CPX-351 to acute lymphoblastic leukemia at high risk of induction mortality?
    Lemoine, Jean
    HEMATOLOGIE, 2020, 26 (06): : 288 - 289
  • [37] A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
    Usuki, Kensuke
    Miyamoto, Toshihiro
    Yamauchi, Takuji
    Ando, Kiyoshi
    Ogawa, Yoshiaki
    Onozawa, Masahiro
    Yamauchi, Takahiro
    Kiyoi, Hitoshi
    Yokota, Akira
    Ikezoe, Takayuki
    Katsuoka, Yuna
    Takada, Satoru
    Aotsuka, Nobuyuki
    Morita, Yasuyoshi
    Ishikawa, Takayuki
    Asada, Noboru
    Ota, Shuichi
    Dohi, Atsushi
    Morimoto, Kensaku
    Imai, Shunji
    Kishimoto, Umi
    Akashi, Koichi
    Miyazaki, Yasushi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (6) : 647 - 659
  • [38] Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
    Riva, Carola
    Minetto, Paola
    Chies, Maria
    Vernarecci, Chiara
    Colombo, Nicoletta
    Rosellini, Sara
    Parodi, Alessia
    Tedone, Elisabetta
    Carminati, Enrico
    Nurra, Clara
    Puglisi, Francesco
    Frello, Michela
    Maio, Elena
    Ferro, Beatrice
    Zecchetti, Giada
    Fugazza, Giuseppina
    Nozza, Paolo
    Cea, Michele
    Lemoli, Roberto Massimo
    Guolo, Fabio
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [39] Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience
    Fianchi, Luana
    Guolo, Fabio
    Marchesi, Francesco
    Cattaneo, Chiara
    Gottardi, Michele
    Restuccia, Francesco
    Candoni, Anna
    La Barbera, Elettra Ortu
    Fazzi, Rita
    Pasciolla, Crescenza
    Finizio, Olimpia
    Fracchiolla, Nicola
    Delia, Mario
    Lessi, Federica
    Dargenio, Michelina
    Bonuomo, Valentina
    Del Principe, Maria Ilaria
    Zappasodi, Patrizia
    Picardi, Marco
    Basilico, Claudia
    Piedimonte, Monica
    Minetto, Paola
    Giordano, Antonio
    Chiusolo, Patrizia
    Prezioso, Lucia
    Buquicchio, Caterina
    Melillo, Lorella Maria Antonia
    Zama, Daniele
    Farina, Francesca
    Mancini, Valentina
    Terrenato, Irene
    Rondoni, Michela
    Urbino, Irene
    Tumbarello, Mario
    Busca, Alessandro
    Pagano, Livio
    CANCERS, 2023, 15 (13)
  • [40] Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
    Riva, Carola
    Minetto, Paola
    Chies, Maria
    Maio, Elena
    Azzanelli, Ylenia
    Zecchetti, Giada
    Colombo, Nicoletta
    Rosellini, Sara
    Parodi, Alessia
    Tedone, Elisabetta
    Carminati, Enrico
    Fugazza, Giuseppina
    Nozza, Paolo
    Cea, Michele
    Lemoli, Roberto Massimo
    Guolo, Fabio
    BLOOD, 2024, 144 : 1482 - 1483
12345